BioSpace News Archive

Pneumonia vaccines are recommended for adults and children for a wide range of clinical conditions. The bacteria Streptococcus pneumoniae is responsible for pneumococcal infections causing otitis media, bacteremia, pneumonia, and meningitis.

Transparency Market Research has published a new report titled, “Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global intravenous immunoglobulin market was valued at US$ 8,983.5 Mn in 2017 and is projected to expand at a CAGR of 8.1% from 2018 to 2026.

Disposable face masks are witnessing higher demand for themselves in current times because of the COVID-19 pandemic. These products are used to protect the face and nose from contamination.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced that they received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Biologics License Application seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug QIXLEEF for Tetra’s clinical trial programs.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities’ Neuroscience Conference.

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone.

Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. “We are delighted that Longitude and BVF are investing in Alpha-9,” said Simon Pimstone, MD, PhD, Chairman of the Board of Directors

Valeo Pharma Inc . a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement (“PLA”) with the Executive Officer of the Ontario Public Drug Program

-- First Quarter Revenues of $251.4 Million Reflect Solid Performance of VIVITROL® and ARISTADA® -- -- Achieves GAAP Loss per Share of $0.14 and Basic and Diluted Non-GAAP Earnings per Share of $0.11, Supported by Disciplined Expense Management -- -- Financial Expectations for 2021 Reiterated --